Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 59

Results For "C"

9946 News Found

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility
News | January 12, 2026

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility

Supports production of AbbVie's current and next-generation immunology and neuroscience medicines


Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility
R&D | January 12, 2026

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants


Novartis to open Florida radioligand facility
News | January 12, 2026

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US


FDA rejects Vanda’s jet lag drug in current form
Drug Approval | January 12, 2026

FDA rejects Vanda’s jet lag drug in current form

Vanda strongly disputes the FDA’s reasoning


Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
News | January 11, 2026

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients


Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
Biotech | January 11, 2026

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism


Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera
News | January 11, 2026

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories


Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy
News | January 11, 2026

Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab


Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
News | January 11, 2026

Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection

The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit